Merck reports Phase II data for Keytruda in HCC

Merck & Co. Inc. (NYSE:MRK) reported data from the Phase II KEYNOTE-224 trial in 104 patients with advanced hepatocellular carcinoma (HCC) previously treated

Read the full 230 word article

User Sign In